Background:Ewing sarcoma (ES) is most common in adolescents and young adults with tendency to affect any bone especially pelvic, femur and chest wall bones. Multimodality approach (multiagent chemotherapy, surgery and/or radiotherapy) is the standard of care in treating localized ES.Purpose of this study: was to present our institution experience in ES treatment and evaluate the clinical outcome including survival and prognostic factors.
Patients and methods: This was a retrospective study including 60 patients with primary Ewing Sarcoma (ES) treated at radiation Oncology section – King Faisal Specialist Hospital and Research Centre (KFSH & RC) – Riyadh, Saudi Arabia between Jan 2005 and April 2018.Results: At diagnosis, median age was 20 (range 14-70) years, thirty five(58.3%) patients were male. Forty one (68.3%) patients had localized disease; extremities were commonest primary site in 29(48.4%) patients. Surgery performed in35 (58.3%) patients and 51(85%) patients received radiation therapy (RT). Median follow-up was 31 months (8-160). Forty four patients had disease progression. Site of first failure was local for ten patients, local and distant failure for ten patients, and distant for Twenty four patients. Five year LRFS, DMFS, PFS,and OS were 69.8%, 35.8% ,26.7% and 60.7% respectively.
Conclusion:The best outcome of ES can be achieved through multidisciplinary team where the upfront step and whole treatment plan are properly selected. Multiple lines of chemotherapy, recent advances of irradiation and surgery of oligometastatic sites may play a role in improving the treatment outcome.
Key Word: Ewing sarcoma, Treatment, Prognostic factors